Home Alzheimer’s Disease Olaparib Maintenance Therapy Improves Survival in Relapsed, BRCA-Positive Ovarian Cancer

Olaparib Maintenance Therapy Improves Survival in Relapsed, BRCA-Positive Ovarian Cancer

Maintenance treatment with olaparib (Lynparza) extended overall survival (OS) by 12.9 months in women with platinum-sensitive relapsed ovarian cancer with BRCA1/2 mutations, compared with placebo, according to randomized phase III trial results presented during a 2020 ASCO Virtual Scientific Program press briefing.1

“Relapsed ovarian cancer is associated with poor outcomes. Therefore, treatment goals include delaying symptomatic disease progression and prolonging survival,” lead study author Andres Poveda, MD, Initia Oncology, Hospital Quironsalud, in Valencia, Spain, said during a pre-recorded presentation. “However, improvements in overall survival are difficult to demonstrate in ovarian cancer trials because of crossover and limited options. Limited progress has been made in improving overall survival in the last two decades.”

In the final analysis of the double-blind,…

Continue Reading to the Source

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Popular

please help us fundraise (501c3 non-profit) : braincancer

I work with OurBrainBank, a start-up non-profit dedicated to moving glioblastoma from terminal to treatable, powered by patients.We're a registered 501c3 non-profit in the...

Cancer and Mental Health Re-post : braincancer

Hello!I would like to thank everyone who participated in my survey these past few months! I received a tremendous response and I truly, truly...

Recent Comments